GlassScriptPhysician profile
Sonya S Addison
NPI 1215199369
$25,280.91
in general payments reported to CMS, 2019-2025
40 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $4,867 · 2021: $8,960 · 2022: $6,567 · 2023: $1,046 · 2024: $1,747 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.26 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15,157.48 | 2021-2025 | Minimed 780g, Guardian Connect, Vanta Adaptivestim |
| Medtronic Minimed, INC. | $4,694.34 | 2019-2020 | |
| Novo Nordisk INC | $863.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $858.91 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $388.20 | 2022-2025 | Evenity, Tepezza, Repatha |
| Abbvie INC. | $372.75 | 2019-2025 | Dalvance, Synthroid |
| Corcept Therapeutics | $353.02 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $302.27 | 2020-2025 | |
| Lilly USA, LLC | $264.28 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Recordati_rare_diseases_inc. | $233.65 | 2023-2025 | Isturisa, Signifor Lar |
| Abbott Laboratories | $218.48 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $159.73 | 2019-2025 | Capvaxive, Gardasil 9, Delstrigo |
| Astrazeneca Pharmaceuticals LP | $148.78 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $142.38 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Averitas Pharma INC. | $134.72 | 2023-2025 | Qutenza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.55 | 2021-2024 | Jardiance |
| Cequr Corporation | $76.79 | 2023-2024 | Cequr Simplicity |
| Viiv Healthcare Company | $67.67 | 2024-2025 | Apretude, Dovato |
| Alexion Pharmaceuticals, INC. | $66.73 | 2024-2025 | Strensiq |
| Paratek Pharmaceuticals, INC. | $65.67 | 2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $63.48 | 2022 | |
| Radius Health, INC. | $49.99 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $49.43 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $45.20 | 2022 | |
| Tandem Diabetes Care, INC. | $42.54 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $42.34 | 2021-2024 | Omnipod |
| La Jolla Pharmaceutical Company | $35.32 | 2024-2025 | Xacduro |
| Beta Bionics, INC. | $30.79 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ferring Pharmaceuticals INC. | $28.83 | 2024 | Rebyota |
| Amneal Pharmaceuticals LLC | $27.34 | 2024 | Unithroid |
| Pfizer INC. | $25.87 | 2024 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.07 | 2024 | |
| Mannkind Corporation | $21.20 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $20.40 | 2025 | |
| Chiesi USA, INC. | $19.92 | 2024 | Mycapssa |
| Glaxosmithkline, LLC. | $13.70 | 2025 | Penmenvy, Arexvy, Shingrix |
| Sun Pharmaceutical Industries INC. | $13.47 | 2020 | |
| Organogenesis INC. | $13.44 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $10.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Addison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.